Brought to you by 
Genelabs and SmithKline in antibacterial lead discovery pact
30 Nov 2004
Executive Summary
Genelabs (developing drugs that target specific genes) and SmithKline Beecham will work together to identify targets on the genes of bacteria that could be regulated by small-molecule drugs.
Deal Industry
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genelabs and SmithKline in antibacterial lead discovery pact
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice